ARArrowhead Pharmaceuticals ARWR · NASDAQ
$59.53 -0.07% (-$0.04)
- Market cap
- $8.41B
- Enterprise value
- $9.22B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 12.6x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -13.1%
- Gross margin
- 100.0%
- Net margin
- -47.8%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.30
- Free float
- 86.7%
About the company
Arrowhead Pharmaceuticals is a U.S.-based biotechnology company focused on developing innovative therapies targeting genetic diseases. The company is particularly known for its advanced RNA interference (RNAi) technology, which enables the "turning off" or regulation of genes associated with various diseases. Arrowhead Pharmaceuticals focuses on developing drugs for the treatment of rare and chronic conditions, including genetic disorders, viral infections, and cardiovascular diseases, aiming to improve treatment outcomes and the quality of life for patients.
Sector
Healthcare
Industry
Biotechnology
CEO
Christopher R. Anzalone
Employees
711
Headquarters
Pasadena
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 51% a year over the last 3 years.
- What to watch: Analysts expect revenue to fall by 44% this fiscal year.
- What to watch: It missed profit estimates 6 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number